SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-21-020145
Filing Date
2021-08-16
Accepted
2021-08-16 16:05:37
Documents
15
Period of Report
2021-08-12
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 2.06: Material Impairments
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 56127
2 ex16-1.htm EX-16.1 6422
3 ex16-1_001.jpg GRAPHIC 2314
4 ex99-1.htm EX-99.1 141111
  Complete submission text file 0001493152-21-020145.txt   402729

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE indp-20210812.xsd EX-101.SCH 3030
6 XBRL LABEL FILE indp-20210812_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE indp-20210812_pre.xml EX-101.PRE 22362
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3649
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 347-480-9760
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

IRS No.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40652 | Film No.: 211177902
SIC: 2834 Pharmaceutical Preparations